| Drug Name |
Salmeterol xinafoate |
| Drug ID |
BADD_D01982 |
| Description |
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol].[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737]
Salmeterol was granted FDA approval on 4 February 1994.[L11542] |
| Indications and Usage |
Salmeterol is indicated in the treatment of asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease.[L11545,L11548,L11551,L11554,L11557] |
| Marketing Status |
approved |
| ATC Code |
R03AC12 |
| DrugBank ID |
DB00938
|
| KEGG ID |
D00687
|
| MeSH ID |
D000068299
|
| PubChem ID |
56801
|
| TTD Drug ID |
D0L5YV
|
| NDC Product Code |
53104-7541; 50909-4102; 64567-0007; 52221-109; 52482-002; 15308-1021; 63190-0650; 14501-0045; 55018-402; 58032-0143; 0173-0521 |
| UNII |
6EW8Q962A5
|
| Synonyms |
Salmeterol Xinafoate | Xinafoate, Salmeterol | Salmeterol | Serevent |
